Prevention of coronary heart diseaseBMJ 2004; 328 doi: https://doi.org/10.1136/bmj.328.7436.405-c (Published 12 February 2004) Cite this as: BMJ 2004;328:405
- Tom Marshall, clinical lecturer (T.P.Marshall@bham.ac.uk)
- Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT
EDITOR—Correspondents responding to my article on bmj.com raise several interesting issues.1 Nevertheless no correspondent disputes either the approach (incremental cost effectiveness analysis) or the fundamental findings: that aspirin and antihypertensive treatment with bendrofluazide and atenolol are markedly more cost effective than statins and clopidogrel.
Conradi et al and O'Donnell indicate that statins may have more side effects than is generally appreciated. Mann doubts the effectiveness of clopidogrel in primary prevention.1 Both points strengthen the paper's conclusions. I agree …